United-Guardian Reports Increased Second Quarter Sales & Earnings
United-Guardian (NASDAQ:UG) reported strong financial results for Q2 and H1 2024. Sales for H1 2024 increased to $6,645,149 from $5,220,623 in 2023, while net income rose to $1,881,667 ($0.41 per share) from $1,217,175 ($0.26 per share). Q2 2024 sales grew to $3,390,205 from $2,650,299 in 2023, with net income increasing to $956,225 ($0.21 per share) from $461,094 ($0.10 per share).
Key highlights include:
- Cosmetic ingredient sales up 84% in Q2 and 115% in H1 2024
- Medical lubricant sales increased 15% in Q2 and 9% in H1 2024
- Pharmaceutical product sales up 3% in Q2 but down 13% in H1 2024 due to a temporary shutdown
The company attributes the growth to increased purchases from its largest cosmetic distributor and recovering Renacidin® sales after production resumed in late March.
United-Guardian (NASDAQ:UG) ha riportato risultati finanziari solidi per il secondo trimestre e il primo semestre del 2024. Le vendite per il primo semestre del 2024 sono aumentate a 6.645.149 dollari rispetto a 5.220.623 dollari nel 2023, mentre il reddito netto è salito a 1.881.667 dollari (0,41 dollari per azione) rispetto a 1.217.175 dollari (0,26 dollari per azione). Le vendite del secondo trimestre del 2024 sono cresciute a 3.390.205 dollari rispetto a 2.650.299 dollari nel 2023, con un reddito netto aumentato a 956.225 dollari (0,21 dollari per azione) rispetto a 461.094 dollari (0,10 dollari per azione).
I punti salienti includono:
- Vendite di ingredienti cosmetici aumentate dell'84% nel secondo trimestre e del 115% nel primo semestre del 2024
- Vendite di lubrificanti medici aumentate del 15% nel secondo trimestre e del 9% nel primo semestre del 2024
- Vendite di prodotti farmacologici aumentate del 3% nel secondo trimestre, ma diminuite del 13% nel primo semestre del 2024 a causa di un'interruzione temporanea
L'azienda attribuisce la crescita all'aumento degli acquisti dal suo più grande distributore di cosmetici e al recupero delle vendite di Renacidin® dopo la ripresa della produzione a fine marzo.
United-Guardian (NASDAQ:UG) reportó resultados financieros fuertes para el segundo trimestre y el primer semestre de 2024. Las ventas del primer semestre de 2024 aumentaron a $6,645,149 desde $5,220,623 en 2023, mientras que el ingreso neto creció a $1,881,667 ($0.41 por acción) desde $1,217,175 ($0.26 por acción). Las ventas del segundo trimestre de 2024 crecieron a $3,390,205 desde $2,650,299 en 2023, con un ingreso neto que aumentó a $956,225 ($0.21 por acción) desde $461,094 ($0.10 por acción).
Los aspectos destacados incluyen:
- Ventas de ingredientes cosméticos aumentadas en un 84% en el segundo trimestre y un 115% en el primer semestre de 2024
- Las ventas de lubricantes médicos aumentaron un 15% en el segundo trimestre y un 9% en el primer semestre de 2024
- Ventas de productos farmacéuticos aumentadas en un 3% en el segundo trimestre, pero disminuidas en un 13% en el primer semestre de 2024 debido a un cierre temporal
La empresa atribuye el crecimiento al aumento de las compras de su mayor distribuidor de cosméticos y la recuperación de las ventas de Renacidin® tras la reanudación de la producción a finales de marzo.
유나이티드 가디언 (NASDAQ:UG)은 2024년 2분기 및 상반기 강력한 재무 성과를 보고했습니다. 2024년 상반기 매출은 2023년 5,220,623달러에서 6,645,149달러로 증가하였고, 순이익은 1,217,175달러($0.26 per share)에서 1,881,667달러($0.41 per share)로 증가했습니다. 2024년 2분기 매출은 2023년 2,650,299달러에서 3,390,205달러로 증가하였으며, 순이익은 461,094달러($0.10 per share)에서 956,225달러($0.21 per share)로 증가했습니다.
주요 하이라이트:
- 2024년 2분기 화장품 원료 매출 84% 증가, 상반기 115% 증가
- 2024년 2분기 의료 윤활제 매출 15% 증가, 상반기 9% 증가
- 2024년 2분기 제약 제품 매출 3% 증가, 상반기 13% 감소 (일시 중지로 인한)
회사는 성장을 최대 화장품 유통업체의 구매 증가와 3월 말 생산 재개 후 Renacidin® 판매 회복에 기인한다고 분석했습니다.
United-Guardian (NASDAQ:UG) a annoncé des résultats financiers solides pour le deuxième trimestre et le premier semestre de 2024. Les ventes pour le premier semestre de 2024 ont augmenté à 6 645 149 $ contre 5 220 623 $ en 2023, tandis que le revenu net a grimpé à 1 881 667 $ (0,41 $ par action) contre 1 217 175 $ (0,26 $ par action). Les ventes du deuxième trimestre 2024 ont augmenté à 3 390 205 $ contre 2 650 299 $ en 2023, avec un revenu net en hausse à 956 225 $ (0,21 $ par action) contre 461 094 $ (0,10 $ par action).
Les points clés à retenir sont :
- Ventes d'ingrédients cosmétiques en hausse de 84 % au 2e trimestre et de 115 % au 1er semestre 2024
- Ventes de lubrifiants médicaux en hausse de 15 % au 2e trimestre et de 9 % au 1er semestre 2024
- Ventes de produits pharmaceutiques en hausse de 3 % au 2e trimestre, mais en baisse de 13 % au 1er semestre 2024 en raison d'une fermeture temporaire
L'entreprise attribue cette croissance à une augmentation des achats de son plus grand distributeur de cosmétiques et à la reprise des ventes de Renacidin® après la reprise de la production fin mars.
United-Guardian (NASDAQ:UG) berichtete über starke finanzielle Ergebnisse im 2. Quartal und 1. Halbjahr 2024. Der Umsatz im 1. Halbjahr 2024 stieg auf 6.645.149 USD von 5.220.623 USD im Jahr 2023, während der Nettogewinn auf 1.881.667 USD (0,41 USD pro Aktie) von 1.217.175 USD (0,26 USD pro Aktie) anstieg. Der Umsatz im 2. Quartal 2024 wuchs auf 3.390.205 USD von 2.650.299 USD im Jahr 2023, wobei der Nettogewinn auf 956.225 USD (0,21 USD pro Aktie) von 461.094 USD (0,10 USD pro Aktie) anstieg.
Wichtige Highlights:
- Verkäufe von kosmetischen Inhaltsstoffen stiegen im 2. Quartal um 84 % und im 1. Halbjahr um 115 %.
- Verkäufe von medizinischen Gleitmitteln stiegen im 2. Quartal um 15 % und im 1. Halbjahr um 9 %.
- Verkäufe von pharmazeutischen Produkten stiegen im 2. Quartal um 3 %, fielen jedoch im 1. Halbjahr um 13 % aufgrund einer vorübergehenden Schließung.
Das Unternehmen führt das Wachstum auf gestiegene Einkäufe seines größten kosmetischen Distributors und die Erholung der Verkäufe von Renacidin® nach der Wiederaufnahme der Produktion Ende März zurück.
- Sales increased by 27.3% to $6,645,149 in H1 2024
- Net income grew by 54.6% to $1,881,667 in H1 2024
- EPS increased from $0.26 to $0.41 in H1 2024
- Q2 2024 sales rose by 28% to $3,390,205
- Q2 2024 net income more than doubled to $956,225
- Cosmetic ingredient sales surged 115% in H1 2024
- Medical lubricant sales grew 9% in H1 2024
- Pharmaceutical product sales decreased 13% in H1 2024 due to a production shutdown
Insights
United-Guardian's Q2 2024 results show significant improvement, with sales increasing by
The substantial growth in United-Guardian's cosmetic ingredient sales, particularly the
HAUPPAUGE, N.Y., Aug. 09, 2024 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the second quarter and first half of 2024. Sales for the six-month period ended June 30th increased from
Donna Vigilante, President of United-Guardian, stated, “We are pleased to announce that sales increased for both the second quarter and the first six months of 2024 compared with the same periods in 2023. Cosmetic ingredient sales increased by
United-Guardian is a manufacturer of cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients.
Contact: | Donna Vigilante |
(631) 273-0900 | |
dvigilante@u-g.com |
NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.
Financial Results for the Three and Six Months Ended June 30, 2024 and 2023 STATEMENTS OF INCOME (unaudited) | ||||||||||||||||
THREE MONTHS ENDED JUNE 30, | SIX MONTHS ENDED JUNE 30, | |||||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||||
Net sales | $ | 3,390,205 | $ | 2,650,299 | $ | 6,645,149 | $ | 5,220,623 | ||||||||
Costs and expenses: | ||||||||||||||||
Cost of sales | 1,561,090 | 1,429,407 | 3,117,580 | 2,523,002 | ||||||||||||
Operating expenses | 602,777 | 574,093 | 1,171,642 | 1,092,039 | ||||||||||||
Research and development expense | 111,660 | 128,729 | 214,642 | 255,688 | ||||||||||||
Total costs and expenses | 2,275,527 | 2,132,229 | 4,503,864 | 3,870,729 | ||||||||||||
Income from operations | 1,114,678 | 518,070 | 2,141,285 | 1,349,894 | ||||||||||||
Other income (expense): | ||||||||||||||||
Investment income | 100,007 | 54,950 | 198,080 | 102,582 | ||||||||||||
Net (loss) gain on marketable securities | (9,501 | ) | 7,479 | 31,995 | 80,180 | |||||||||||
Total other income | 90,506 | 62,429 | 230,075 | 182,762 | ||||||||||||
Income before provision for income taxes | 1,205,184 | 580,499 | 2,371,360 | 1,532,656 | ||||||||||||
Provision for income taxes | 248,959 | 119,405 | 489,693 | 315,481 | ||||||||||||
Net income | $ | 956,225 | $ | 461,094 | $ | 1,881,667 | $ | 1,217,175 | ||||||||
Earnings per common share (basic and diluted) | $ | 0.21 | $ | 0.10 | $ | 0.41 | $ | 0.26 | ||||||||
Weighted average shares (basic and diluted) | 4,594,319 | 4,594,319 | 4,594,319 | 4,594,319 |
FAQ
What were United-Guardian's (UG) Q2 2024 financial results?
How did United-Guardian's (UG) cosmetic ingredient sales perform in H1 2024?
What caused the decrease in United-Guardian's (UG) pharmaceutical product sales in H1 2024?